Testing intravitreal toxicity of bevacizumab (Avastin).

@article{Manzano2006TestingIT,
  title={Testing intravitreal toxicity of bevacizumab (Avastin).},
  author={Roberta Pereira de Almeida Manzano and Gholam A. Peyman and Palwasha Khan and Muhamet Kivilcim},
  journal={Retina},
  year={2006},
  volume={26 3},
  pages={257-61}
}
PURPOSE To evaluate the retinal toxicity of varying doses of bevacizumab when injected intravitreally in rabbits. Bevacizumab has been approved by the US Food and Drug Administration for the treatment of metastatic colorectal cancer. MATERIALS AND METHODS Twelve New Zealand albino rabbits were used for this study and divided into four groups. Four concentrations of bevacizumab were prepared: 500 microg/0.1 mL, 1.0 mg/0.1 mL, 2.5 mg/0.1 mL, and 5.0 mg/0.2 mL. Each concentration was injected… CONTINUE READING